Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Study: Over half of the online pharmacies selling chemotherapy drugs operate unsafely or illegally

Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN-; Journal of the National Comprehensive Cancer Network.

28 Jul 2022

Biochemist finds new way to protect healthy leukocytes during chemotherapy

A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection.

14 Jul 2022

Study reveals a specific metabolic adaptation in some patients with acute myeloid leukemia

An article published in the journal Nature Communications describes a specific metabolic adaptation in some patients with acute myeloid leukemia affected by tandem mutations in the FLT3 gene.

13 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Natural compounds often have promising therapeutic potential but their use to treat diseases is hampered due to toxicity or non-desirable effects.

27 Jun 2022

Computer simulation model helps understand why chemotherapy resistance occurs

Understanding why and how chemotherapy resistance occurs is a major step toward optimizing treatments for cancer.

21 Jun 2022

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

6 Jun 2022

Three-drug therapy with autologous stem cell transplant improves progression-free survival for multiple myeloma patients

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.

6 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022

Risk factors for COVID-19 in patients with hematological malignancies

Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.

26 May 2022

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.

23 May 2022

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have reduced long-term survival rates compared to their peers without cancer.

13 May 2022

Researchers make breakthrough in overcoming drug resistance in a rare, devastating blood cancer

South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within a few years.

9 May 2022

Novel method could bring life-saving benefits of CAR T-cell therapy to patients with acute myeloid leukemia

Massachusetts General Hospital researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.

28 Apr 2022

CRISPR/Cas9 deletions induce adverse on-target genomic effects

Researchers utilized a CRISPR/Cas9 system to evaluate the usage of tRNA by deleting two tRNA genes from the genomes of hyper hepatocellular carcinoma and human near-haploid chronic myeloid leukemia cells.

27 Apr 2022

Researchers discover a novel signaling pathway that defines interferon responses in blood cancers

Northwestern Medicine investigators have discovered a novel signaling pathway activated by interferons, a group of immune system proteins, that suppresses the anti-tumor response of interferons in patients with a particular type of blood cancer, according to findings published in Nature Communications.

19 Apr 2022

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

13 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

Decisive role of PDK1 enzyme in acute myeloid leukemia revealed

Acute myeloid leukemia (AML) remains harder to treat therapeutically due to the high existing genetic heterogeneity not only between patients but also between the population of subclones of cancer cells within the same person.

30 Mar 2022

Understanding a New Mutation in Pediatric AML

News-Medical speaks to Dr. Jeffery Klco about acute myeloid leukemia (AML) and his recent research that is helping us to understand a new mutation in pediatric AML.

25 Mar 2022